Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Stock Information for Coherus Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Coherus Oncology Inc.

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.